lockheed-taqnia-to-build-new-ground-systems-for-saudi-arabia
Category: #health  By Saipriya Iyer  Date: 2020-06-09
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

lockheed-taqnia-to-build-new-ground-systems-for-saudi-arabia

Alnylam Pharmaceuticals, a renowned RNAi therapeutics firm, has reportedly announced positive Phase 3 outcomes from the company’s ILLUMINATE-A study for assessing lumasiran, its investigational RNAi therapeutic candidate targeting HAO1 (hydroxyacid oxidase 1)- the gene encoding GO (glycolate oxidase), that is currently under development to treat PH1 (primary hyperoxaluria type 1).

The positive clinical data was presented during a session at the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association) International Congress that was conducted between June 6 and 9 as a virtual event.

Lumasiran reached the ILLUMINATE-A primary endpoint with a substantial 53.5% mean reduction into urinary oxalate in comparison with placebo and displayed a 65.4% mean reduction inside urinary oxalate in comparison to baseline.

Each tested trial secondary endpoint was met, including the patient proportion that is achieving normalization (52%) or near-normalization (84%) of urinary oxalate, relative to zero percent present within the placebo group. Administration of lumasiran was linked with an encouraging tolerability and safety profile, without any severe or serious AEs (adverse events) and with mild ISRs (injection site reactions) as the most regular drug-related AE.

Alnylam’s President of R&D, Akshay Vaishnaw, Ph.D., M.D., stated that the company is thrilled to showcase positive Phase 3 outcomes of the ILLUMINATE-A lumasiran study. The reported sustained and substantial reductions in plasma and urinary oxalate, show that lumasiran addresses the PH1’s underlying pathophysiology by reducing the generation of toxic metabolite responsible for clinical manifestations of this progressive and serious disease.

The company believes that the drug candidate is capable of making a positive impact on the disease manifestations, which also includes renal stones and nephrocalcinosis, as well as overall disease progression which the firm is continuing to examine during the ongoing ILLUMINATE program.

Vaishnaw further added that the ILLUMINATE-A trial is the sixth positive Phase 3 trial for an investigational RNAi therapeutic, and the company believes it further emphasizes the transformational capability of this modality as a completely new medicinal class. Assuming suitable regulatory reviews, the company looks forward to providing lumasiran for patients suffering from PH1 across the world.

Source credit: https://apnews.com/2c725a9cb70d4fb3a9a583397572eee0



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...